Journal of Clinical Endocrinology & Metabolism, Vol 69, 1127-1132, Copyright © 1989 by Endocrine Society

ARTICLES

Effects of growth hormone therapy on thyroid function of growth hormone- deficient adults with and without concomitant thyroxine-substituted central hypothyroidism

JO Jorgensen, SA Pedersen, P Laurberg, J Weeke, NE Skakkebaek and JS Christiansen
Second University Clinic of Internal Medicine, Aarhus, Kommunehospital, Denmark.

Administration of human GH to GH-deficient patients has yielded conflicting results concerning its impact on thyroid function, ranging from increased resting metabolic rate to induction of hypothyroidism. However, most studies have been casuistic or uncontrolled and have used pituitary-derived GH of varying purity, often contaminated with TSH. Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr). One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9). Serum T4 (nanomoles per L) decreased in both groups after GH treatment [group I, 100 +/- 8 (mean +/- SE) vs. 89 +/- 8 (P less than 0.01); group II, 145 +/- 18 vs. 115 +/- 10 (P less than 0.05)]. Conversely, GH treatment caused an increase in serum T3 (nanomoles per L) in both groups [group I, 1.9 +/- 0.1 vs. 2.0 +/- 0.1 (P less than 0.1); group II, 1.7 +/- 0.1 vs. 1.9 +/- 0.1 (P less than 0.05)]. Similar changes were seen in serum free T4 and T3. The serum T3 level during the placebo period of group I was significantly lower than that in an age-matched reference group (P less than 0.02). Serum rT3 (nanomoles per L) was low in group I and decreased significantly, as in group II, after GH treatment [group I, 0.26 +/- 0.02 (placebo) vs. 0.20 +/- 0.02 (GH; P less than 0.01); group II, 0.38 +/- 0.05 (placebo) vs. 0.29 +/- 0.02 (GH; P less than 0.01)]. Serum TSH decreased in both groups during GH therapy, though not significantly. Serum thyroglobulin was unaltered and did not differ from that in the reference group. In conclusion, our data are consistent with a GH-induced enhancement of peripheral deiodination of T4 to T3. GH thus seems to play an important role, either directly or indirectly, in the regulation of peripheral T4 metabolism.

This article has been cited by other articles:

				H. R. Mogul, P. D. K. Lee, B. Y. Whitman, W. B. Zipf, M. Frey, S. Myers, M. Cahan, B. Pinyerd, and A. L. Southren Growth Hormone Treatment of Adults with Prader-Willi Syndrome and Growth Hormone Deficiency Improves Lean Body Mass, Fractional Body Fat, and Serum Triiodothyronine without Glucose Impairment: Results from the United States Multicenter Trial J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1238 - 1245. [Abstract] [Full Text] [PDF]

				M. R. A. Martins, F. C. Doin, W. R. Komatsu, T. L. Barros-Neto, V. A. Moises, and J. Abucham Growth Hormone Replacement Improves Thyroxine Biological Effects: Implications for Management of Central Hypothyroidism J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4144 - 4153. [Abstract] [Full Text] [PDF]

				J. Gibney, M.-L. Healy, and P. H. Sonksen The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport Endocr. Rev., October 1, 2007; 28(6): 603 - 624. [Abstract] [Full Text] [PDF]

				M Saugy, N Robinson, C Saudan, N Baume, L Avois, and P Mangin Human growth hormone doping in sport Br. J. Sports Med., July 1, 2006; 40(suppl_1): i35 - i39. [Abstract] [Full Text] [PDF]

				R. P. Peeters, A. W. van den Beld, H. van Toor, A. G. Uitterlinden, J. A. M. J. L. Janssen, S. W. J. Lamberts, and T. J. Visser A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 256 - 263. [Abstract] [Full Text] [PDF]

				S. Porretti, C. Giavoli, C. Ronchi, G. Lombardi, M. Zaccaria, D. Valle, M. Arosio, and P. Beck-Peccoz Recombinant Human GH Replacement Therapy and Thyroid Function in a Large Group of Adult GH-Deficient Patients: When Does L-T4 Therapy Become Mandatory? J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2042 - 2045. [Abstract] [Full Text] [PDF]

				A. C. Bianco, D. Salvatore, B. Gereben, M. J. Berry, and P. R. Larsen Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocr. Rev., February 1, 2002; 23(1): 38 - 89. [Abstract] [Full Text] [PDF]

				H. Nørrelund, K. S. Nair, J. O. L. Jørgensen, J. S. Christiansen, and N. Møller The Protein-Retaining Effects of Growth Hormone During Fasting Involve Inhibition of Muscle-Protein Breakdown Diabetes, January 1, 2001; 50(1): 96 - 104. [Abstract] [Full Text]

				S. B. Pedersen, K. Kristensen, S. Fisker, J. O. L. Jørgensen, J. S. Christiansen, and B. Richelsen Regulation of Uncoupling Protein-2 and -3 by Growth Hormone in Skeletal Muscle and Adipose Tissue in Growth Hormone-Deficient Adults J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4073 - 4078. [Abstract] [Full Text]

				D. T. Wyatt, N. Gesundheit, and B. Sherman Changes in Thyroid Hormone Levels during Growth Hormone Therapy in Initially Euthyroid Patients: Lack of Need for Thyroxine Supplementation J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3493 - 3497. [Abstract] [Full Text]

				G. Van den Berghe, F. de Zegher, R. C. Baxter, J. D. Veldhuis, P. Wouters, M. Schetz, C. Verwaest, E. Van der Vorst, P. Lauwers, R. Bouillon, et al. Neuroendocrinology of Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination with Growth Hormone Secretagogues J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 309 - 319. [Abstract] [Full Text]

				P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]